Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Novo Nordisk (0QIU) Gets a Buy from UBS
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Zacks Investment Research on MSN20h
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
Novo Nordisk (NVO) ended the recent trading session at $75.89, demonstrating a +1.47% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...
Altimmune rises amid buyout rumors and R&D updates
Shares of Altimmune (NASDAQ:ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors on Wall Street a day after issuing notable updates on its lead candidate, ...
pharmaphorum18h
Why the Novo Nordisk Foundation is betting big on stem cells
In my last column about the Novo Nordisk Foundation, I wrote about the company’s efforts in anti-microbial resistance, an example of an area where impact investment was necessary to combat ...